E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain

The Smart Label Simplifies and Shortens Expiry Updates Allowing for Considerable Time and Cost Savings

E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging. More>>

WORLD’S FIRST PCM CARGO COVER

A British team of scientists at TLX Cargo Ltd have invented the worlds Cargo Cover/Thermal blanket that incorporates Phase Change Material (PCM) into it`s structure, solved the problem of hot lane temperature excursions on the tarmac. More>>

NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel

More approvals and more novel drugs, Small and Medium Sized Pharma Dominate, Precedence setting FDA oncology approval

Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this year’s DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents. More>>

POP TEST ADDRESSES THE PROBLEM OF UNRELIABLE DATA FROM CONTINUOUS GLUCOSE MONITORS

A major insight relating to the unreliability of data from continuous glucose monitors was published in the Nature journal, “Scientific Reports”, by Neil Theise, MD., the Lead Scientist of Pop Test, LLC and colleagues. The discovery of the “Interstitium”, a newfound human organ, by Dr. Theise and his collaborators, can be viewed by using the link https://www.nature.com/articles/s41598-018-23062-6 Continual glucose monitoring via an indwelling cutaneous needle measuring glucose in interstitial fluid (now identified to be in the “interstitium”) has been a game changer in the treatment of type 1 diabetes mellitus because of its accuracy. However, the needles used to collect this glucose containing fluid often fail in as little as a week. Despite the reliance on fluid from this space, the microanatomy of the interstitium has never been defined. The sensors currently in use were developed with the presumption of interstitial fluid being located somewhere in the sub-epidermal layers of the skin, but the actual anatomy relating to needle placement was always unclear. More>>

When space is tight

Existing packaging lines can be retrofitted for serialization tasks, achieving a maximum of space savings and process reliability: if required, the system comes with an integrated checkweigher and tamper-evident labeler.   More>>

Dempsey Demystifies Regulatory Cycle at DIA Europe

Sheena Dempsey Speaks at DIA Europe 2018

March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director, Sheena Dempsey, will present “Demystifying the Multilingual Complexities in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM (CET), in Basel, Switzerland. More>>

PCI’s Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing

Philadelphia, USA- March 19, 2018. Global pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce a laboratory expansion at its site in Tredegar, Wales, UK.  More>>

Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare

Driving down turnaround times (TATs), to enable a more rapid diagnosis and treatment of patients is the key philosophy of Source BioScience.

As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips. More>>